22nd Century Group Inc (XXII) Stock Rating Upgraded by Zacks Investment Research
22nd Century Group Inc (NYSE:XXII) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company’s products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. “
Separately, Chardan Capital increased their target price on shares of 22nd Century Group from $3.50 to $11.50 and gave the company a “buy” rating in a research note on Monday.
Shares of 22nd Century Group (NYSE:XXII) traded up 0.37% on Wednesday, hitting $2.68. The stock had a trading volume of 2,046,408 shares. The stock has a 50 day moving average of $2.76 and a 200 day moving average of $1.93. The firm’s market cap is $275.40 million. 22nd Century Group has a 12-month low of $0.81 and a 12-month high of $3.50.
ILLEGAL ACTIVITY NOTICE: “22nd Century Group Inc (XXII) Stock Rating Upgraded by Zacks Investment Research” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/18/22nd-century-group-inc-xxii-raised-to-hold-at-zacks-investment-research.html.
In other 22nd Century Group news, VP Michael Robert Moynihan sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $2.67, for a total value of $133,500.00. Following the transaction, the vice president now owns 867,220 shares in the company, valued at approximately $2,315,477.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. National Asset Management Inc. boosted its holdings in shares of 22nd Century Group by 13.7% during the 1st quarter. National Asset Management Inc. now owns 172,000 shares of the biotechnology company’s stock worth $204,000 after buying an additional 20,700 shares during the period. Virtu KCG Holdings LLC boosted its holdings in shares of 22nd Century Group by 300.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 126,106 shares of the biotechnology company’s stock worth $221,000 after buying an additional 94,650 shares during the period. Northern Trust Corp boosted its holdings in shares of 22nd Century Group by 22.3% during the 2nd quarter. Northern Trust Corp now owns 133,797 shares of the biotechnology company’s stock worth $234,000 after buying an additional 24,401 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of 22nd Century Group by 17.6% during the 2nd quarter. Vanguard Group Inc. now owns 2,894,322 shares of the biotechnology company’s stock worth $5,065,000 after buying an additional 432,450 shares during the period.
22nd Century Group Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for 22nd Century Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.